Literature DB >> 16564798

A randomized, masked, cross-over trial of lisinopril for inflammatory macular edema.

Bram van Kooij1, Rob Fijnheer, Joke de Boer, Ninette ten Dam-van Loon, Imke Bartelink, Mark Roest, Aniki Rothova.   

Abstract

PURPOSE: To analyze the effect of angiotensin-converting enzyme (ACE) inhibitor lisinopril on inflammatory cystoid macular edema and visual acuity.
DESIGN: Randomized, double-blind, placebo-controlled cross-over trial.
METHODS: setting: Outpatient clinic of the Department of Ophthalmology at the University Medical Center of Utrecht. patients: Forty patients with inflammatory cystoid macular edema were included. intervention: Each patient received lisinopril (10 mg daily) or placebo for three months. After two months of a lisinopril/placebo free wash-out period, the groups received the reverse study medication for three months. Fluorescein angiography was performed to evaluate the retina. main outcome measures: Cystoid macular edema, best-corrected visual acuity and contrast sensitivity.
RESULTS: Lisinopril had no effect on cystoid macular edema, visual acuity, papillary leakage, retinal vasculitis, and choroidal leakage. In a subgroup analysis, we observed a decrease in blood pressure (lisinopril, 14 of 36 patients; placebo, 5 of 36 patients; P = .02) and a decrease in morning urinary albumin excretion (lisinopril, 23 of 35 patients; placebo 10 of 34 patients, P = .003) was observed.
CONCLUSIONS: Although lisinopril had no effect on inflammatory cystoid macular edema and visual acuity, we found a positive effect on the vascular system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16564798     DOI: 10.1016/j.ajo.2005.11.056

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  An evidence-based systematic review of the off-label uses of lisinopril.

Authors:  Seyyed-Reza Sadat-Ebrahimi; Neda Parnianfard; Nafiseh Vahed; Hossein Babaei; Morteza Ghojazadeh; Sydney Tang; Amir Azarpazhooh
Journal:  Br J Clin Pharmacol       Date:  2018-09-11       Impact factor: 4.335

2.  Posterior segment inflammatory outcomes assessed using fluorescein angiography in the STOP-UVEITIS study.

Authors:  Mohammad Ali Sadiq; Muhammad Hassan; Rubbia Afridi; Muhammad Sohail Halim; Diana V Do; Yasir J Sepah; Quan Dong Nguyen
Journal:  Int J Retina Vitreous       Date:  2020-10-06

3.  Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis).

Authors:  Ilknur Tugal-Tutkun; Carl P Herbort; Moncef Khairallah
Journal:  Int Ophthalmol       Date:  2008-09-16       Impact factor: 2.031

4.  Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction.

Authors:  Toshihide Kurihara; Yoko Ozawa; Susumu Ishida; Hideyuki Okano; Kazuo Tsubota
Journal:  Int J Inflam       Date:  2012-03-22

5.  Ocular kinetics and safety of intravitreally injected angiotensin converting enzyme inhibitor lisinopril.

Authors:  Madhu Nath; Nabanita Halder; Parijat Chandra; Sundararajan Baskar Singh; Ashok Kumar Deorari; Atul Kumar; Thirumurthy Velpandian
Journal:  Int J Retina Vitreous       Date:  2018-11-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.